A Case-control Study on the Differentiation Between Cough Variant Asthma and Chronic Cough

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06199830

Enrollment

645

Registered

2024-01-10

Start date

2022-03-01

Completion date

2023-08-31

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

small airway dysfunction, cough variant asthma, Chronic cough

Brief summary

this study aimed to compare characters in pulmonary function of patients with cough variant asthma and chronic cough and establish a diagnostic model.

Detailed description

the investigators retrospectively collected information from patients with chronic cough who underwent pulmonary tests at the First Affiliated Hospital of Zhejiang Chinese Medical University from January 2019 to December 2019. Data of external test were also from the First Affiliated Hospital of Zhejiang Chinese Medical University, and time period was from January 2023 to April 2023.Pulmonary function test and methacholine challenge test was performed by professional technicians. Characters between patients with cough variant asthma and chronic cough were compared to establish a diagnostic model.

Interventions

DIAGNOSTIC_TESTpositive bronchial provocation test

Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* (1) age from 18 years old to 65 years old; (2) clinical diagnosis of CVA and CC .

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
positive bronchial provocation test	up to 1 week	Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%

Secondary

Measure	Time frame	Description
small airway dysfuction	up to 1 week	MMEF% pred, FEF50% pred, FEF75% pred

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026